C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026)
C4 Therapeutics (CCCC) recorded quarterly EBITDA Margin of 414.52% in Q1 2026, down 121.92% quarter-over-quarter from 186.78% in Q4 2025, and down 5071.0% on a YoY basis from 8.34% in Q1 2025.
C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' EBITDA Margin history runs 8 years deep, the most recent figure standing at 414.52% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 5071.0% year-over-year to 414.52%; the TTM figure through Mar 2026 stood at 298.96% (down 4042.0% YoY), while the FY2025 annual figure was 292.09%, up 337.0% from the prior year.
- EBITDA Margin was 414.52% for Q1 2026 at C4 Therapeutics, down from 186.78% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 148.06% in Q2 2024 to a low of 1322.3% in Q2 2023.
- Historically, EBITDA Margin has averaged 556.17% across 5 years, with a median of 414.52% in 2026.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin tumbled 117727 bps in 2022, then surged 117424 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 1258.34% in 2022, then grew by 17 bps to 1041.92% in 2023, then soared by 35 bps to 675.58% in 2024, then surged by 72 bps to 186.78% in 2025, then tumbled by 122 bps to 414.52% in 2026.
- The last three EBITDA Margin figures came in at 414.52% (Q1 2026), 186.78% (Q4 2025), and 285.39% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | -414.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -414.52% |
| Dec 31, 2025 | -186.78% |
| Sep 30, 2025 | -285.39% |
| Jun 30, 2025 | -403.73% |
| Mar 31, 2025 | -363.80% |
| Dec 31, 2024 | -675.58% |
| Sep 30, 2024 | -154.74% |
| Jun 30, 2024 | -148.06% |
| Mar 31, 2024 | -941.56% |
| Dec 31, 2023 | -1,041.92% |
| Sep 30, 2023 | -236.33% |
| Jun 30, 2023 | -1,322.30% |
| Mar 31, 2023 | -880.90% |
| Dec 31, 2022 | -1,258.34% |
| Sep 30, 2022 | -485.43% |
| Jun 30, 2022 | -204.88% |
| Mar 31, 2022 | -450.68% |
| Dec 31, 2021 | -81.07% |
| Sep 30, 2021 | -291.40% |
| Jun 30, 2021 | -230.60% |